Bio-Techne Expands AI-Designed Protein Portfolio for Cell Therapy

The expansion focuses on addressing the volatility inherent in complex biological signaling. When cell therapies move toward clinical scale, minor fluctuations in inputs often lead to inconsistent results. Bio-Techne’s latest additions—including variants of FGF-4, FGF-7, FGF-8b, IL-3, and a hyperactive IL-15—are engineered to withstand the rigors of long-term culture and elevated temperatures.

Early feedback suggests these tools provide a practical edge in clinical development. Dr. Branden Moriarity of the University of Minnesota noted that the IL-2 heat-stable agonist has shown a distinct advantage in expanding patient-derived Tumor-Infiltrating Lymphocytes, a process frequently hampered by high failure rates. By enhancing the stability and activity of these signaling molecules, the company intends to lower the cost of goods for advanced therapies while ensuring that performance remains consistent throughout the production lifecycle.